

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Tomoaki TAKAKURA et al.

Application No.: 10/584,447

Confirmation No.: 4157

Filed: June 22, 2006

Art Unit: 1615

For: PROCESS FOR PRODUCING PROTEIN-  
POLYMER COMPLEX

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT**  
**(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL**  
**REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE**  
**1.114 RCE APPLICATION)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

- ☒ a. Copies of cited U.S. patents and patent application publications are not included.  
Copies of foreign patent documents and non-patent literature are included.

☐ b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

☐ c. REFERENCES PREVIOUSLY CITED OR SUBMITTED - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

☐ a. DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

☒ b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows: **English language Abstracts are provided for JP-10-191972-A and JP-11-192084-A.**

☐ c. ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

☐ d. OTHER - The following additional information is provided for the Examiner's consideration.

IV. FEES (check one box)

☐ a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

☐ b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

☐ c. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required.  
(This section is not to be used with RCE's.)

☐ d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.

☐ e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.

☒ f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). **No fee or statement is required.** In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).

☐ g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

☐ No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.  
or

☒ See the statement above. No fee is required.

V. STATEMENT UNDER 37 C.F.R. § 1.97(c)

(check only one box)

The undersigned hereby states that:

☐ a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or

☐ b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

☐ d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES (check one box)

☐ The required fee is listed on the attached Fee Transmittal.


☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: June 27, 2007

Respectfully submitted,

By   
Mark J. Nuell  
Registration No.: 36,623  
BIRCH, STEWART, KOLASCH & BIRCH, LLP  
8110 Gatehouse Road  
Suite 100 East  
P.O. Box 747  
Falls Church, Virginia 22040-0747  
(858) 792-8855  
Attorney for Applicant

Attachment(s):

- ☒ PTO-SB08
- ☒ Documents
- ☐ Foreign Search Report
- ☐ Fee
- ☐ Other:

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/584,447	
			Filing Date	June 22, 2006	
			First Named Inventor	Tomoaki Takakura et al.	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	0032—0291PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA*	US-4,179,337	12-18-1979	Davis et al.	
	AB*	US-4,732,863	03-22-1988	Tomasi et al.	
	AC*	US-5,605,976	02-25-1997	Martinez et al.	
	AD*	US-5,690,929	11-25-1997	Lishko et al.	
	AE*	US-5,716,797	02-10-1998	Danno et al.	
	AF*	US-5,834,273	11-10-1998	Futatsugi et al.	
	AG*	US-5,861,154	01-19-1999	Soda et al.	
	AH*	US-5,985,540	11-16-1999	Tan et al.	
	AI*	US-6,461,851	10-08-2002	Tan	
	AJ*	US-6,395,507	05-28-2002	Bongs et al.	
	AK*	US-6,475,767	11-05-2002	Akita et al.	
	AL*	US-2004/0110164	06-10-2004	Inagaki et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	JP-10-191972-A	07-28-1998	Higo Yukiko et al.		
	BB	JP-11-192084-A	07-21-1999	Yoshino Manabu et al.		
	BC	WO-94/11535-A1	05-26-1994	Valeryi Lishiko		
	BD	WO-96/40284-A1	12-19-1996	Yuying Tan et al.		
	BE	WO-00/44808-A1	08-03-2000	Jeffrey A. Hubbell et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 301.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/584,447	
			Filing Date	June 22, 2006	
			First Named Inventor	Tomoaki Takakura et al.	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	0032—0291PUS1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Bullock, John et al., (1997) Comparison of REsults of Various Methods Used to Determine the Extent of Modification of Methoxy Polyethylene Glycol 5000-Modified Bovine Cupri-Zinc Superoxide Dismutase, Analytical Biochemistry, Vol. 254, pps. 254-262	
	CB	Ellman, George L., (1959) Tissue Sulphydryl Groups, Archives of Biochemistry and Biophysics, Vol. 82, pps 70-77	
	CC	Inoue, Hiroyuki et al., (1995) Structural Analysis of the L-Methionine γ-Lyase Gene From Pseudomonas putida, J.Biochem., Vol 117, pps. 1120-1125	
	CD	Jones, Barry N., et al., (1983) o-Phthaldialdehyde Precolumn Derivatization and Reversed-Phase High-Performance Liquid Chromatography of Polypeptide Hydrolysates and Physiological Fluids, Journal of Chromatography, Vol. 266, pps. 471-482	
	CE	Karr, Laurel J., et al., PEG-Antibody in Cell Extraction, Use of Poly(ethylene Glycol)-Modified Antibody in Cell Extraction, Methods in Enzymology, Vol. 228, pps. 377-390	
	CF	Kreis, Willi et al., (August 1973), Biological Effects of Enzymatic Deprivation of L-Methionine in Cell Culture and an Experimental Tumor, Cancer Research, Vol. 33, pps. 1862-1865	
	CG	Kreis, Willi et al., (August 1973) Isolation and Purification of L-Methionine-α-deamino-γ-mercaptopmethane-Lyase (L-Methioninase) from Clostridium sporogenes, Cancer Research, Vol. 33, pps. 1866-1869	
	CH	Nakayama, Toru et al., (1988) Chemical Modification of Cysteine Residues of L-Methionine γ-Lyase, Agric. Biol. Chem., Vol. 52, pps. 177-183	
	CI	Nakayama, Toru et al., (1988), Specific Labeling of the Essential Cysteine Residue of L-Methionine γ-Lyase with a Cofactor Analogue N-(Bromoacetyl)pyridoxamine Phosphate, Biochemistry, Vol. 27, pps. 1587-1591	
	CJ	Tan, Yuying et al., (1998) Polyethylene Glycol Conjugation of Recombinant Methioninase for Cancer Therapy, Protein Expression and Purification, Vol. 12, pps. 45-52	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--